Fulcrum Therapeutics (FULC) Change in Accured Expenses (2018 - 2026)

Fulcrum Therapeutics (FULC) has 9 years of Change in Accured Expenses data on file, last reported at -$3.8 million in Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 12.75% year-over-year to -$3.8 million in Q1 2026; TTM through Mar 2026 was $599000.0, a 232.82% increase from a year earlier, with the FY2025 full-year figure at $1.0 million, up 199.32% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at -$3.8 million, down from $2.3 million in the prior quarter.
• Over the last five years, Change in Accured Expenses for FULC reached as high as $5.8 million in Q2 2022 and fell as low as -$4.5 million in Q3 2022.
• Historically, Change in Accured Expenses has averaged -$237823.5 across 5 years, with a median of $587000.0 in 2025.
• Across the five-year window, Change in Accured Expenses slumped 289.74% in 2022 and jumped 525.16% in 2024, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.6 million in 2022, then plunged by 41.81% to $909000.0 in 2023, then sank by 170.41% to -$640000.0 in 2024, then surged by 457.97% to $2.3 million in 2025, then plunged by 264.38% to -$3.8 million in 2026.
• Per Business Quant data, the three most recent Change in Accured Expenses figures were -$3.8 million in Q1 2026, $2.3 million in Q4 2025, and $1.5 million in Q3 2025.